Jason Damsker, MD
Hematology & Oncology · Horsham, PANPI 1427068683
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 51 manufacturers, the largest accounting for just 17.1%. Reporting peaked in 2024 at $5,685 and has fallen 84.8% since, to $866 in 2025.
Across 242 payments — averaging $48.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Sanofi$2K
- Rigel Pharmaceuticals, Inc.$1K
- Daiichi Sankyo Inc.$1K
- Genentech USA, Inc.$951
- Johnson & Johnson$482
- plus $4K from 45 others
Across 11 payments — averaging $2016.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$19K
- Pharmacyclics LLC, An Abbvie Company$3K
- AstraZeneca$250
What the payments were for
- Consulting fees$5,32645%
- Speaking & faculty fees$1,20010%
- Food & beverage$5,21944%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,790 in reported general payments places this provider in the 75th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 52 | $963,580 |
| Lenalidomide | 36 | $445,317 |
| VenclextaVenetoclax | 30 | $414,390 |
| PomalystPomalidomide | 16 | $363,380 |
| WeliregBelzutifan | 12 | $363,051 |
| NinlaroIxazomib Citrate | 20 | $285,345 |
| InlytaAxitinib | 13 | $228,228 |
| EliquisApixaban | 256 | $191,710 |
| ImbruvicaIbrutinib | 14 | $171,832 |
| IbrancePalbociclib | 11 | $159,981 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 17 | $151,215 |
| RevlimidLenalidomide | 11 | $134,289 |
| XareltoRivaroxaban | 115 | $83,000 |
| Imatinib Mesylate | 12 | $13,532 |
| Fondaparinux Sodium | 18 | $12,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $179 | $963,58052 claims |
| PfizerInlyta, Eliquis, Ibrance | $356 | $579,919280 claims |
| AbbVieVenclexta | $65 | $414,39030 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $323 | $363,38016 claims |
| MerckWelireg | $213 | $363,05112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $2,015 | $285,34520 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $84 | $171,83214 claims |
| Bristol Myers SquibbRevlimid | $119 | $134,28911 claims |
| Johnson & JohnsonXarelto | $482 | $83,000115 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $15 | $1,432117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Horsham
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.